Parsaclisib
- Generic Name
- Parsaclisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22ClFN6O2
- CAS Number
- 1426698-88-5
- Unique Ingredient Identifier
- OS7097575K
- Background
Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
- Associated Conditions
- -
- Associated Therapies
- -
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 177
- Registration Number
- NCT04551053
- Locations
- ๐บ๐ธ
Emory University, Atlanta, Georgia, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธCleveland Clinic, Cleveland, Ohio, United States
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 252
- Registration Number
- NCT04551066
- Locations
- ๐บ๐ธ
Kelsey Seybold Clinic, Houston, Texas, United States
๐ง๐ชA.Z. St.-Jan A.V., Brugge, Belgium
๐บ๐ธOregon Health & Science University, Portland, Oregon, United States
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
- Conditions
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 112
- Registration Number
- NCT04509700
- Locations
- ๐บ๐ธ
Uab Comprehensive Cancer Center, Birmingham, Alabama, United States
๐บ๐ธUniversity of Alabama At Birmingham, Birmingham, Alabama, United States
๐บ๐ธMayo Clinic Rochester, Phoenix, Arizona, United States
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 42
- Registration Number
- NCT04434937
- Locations
- ๐ฏ๐ต
Hyogo College of Medicine Hospital, Hyogo, Japan
๐ฏ๐ตShizuoka Cancer Center, Shizuoka, Japan
๐ฏ๐ตNho Shikoku Cancer Center, Matsuyama, Japan
Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
- Conditions
- Ann Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Marginal Zone LymphomaAnn Arbor Stage IV Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Marginal Zone LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT04323956
- Locations
- ๐บ๐ธ
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
๐บ๐ธMayo Clinic in Florida, Jacksonville, Florida, United States
๐บ๐ธMayo Clinic in Rochester, Rochester, Minnesota, United States
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Registration Number
- NCT04142554
A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03780166
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT03688152
- Locations
- ๐บ๐ธ
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
๐บ๐ธUniversity of Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธClinical Research Alliance, Lake Success, New York, United States
A Study of INCB050465 in Primary Sjรถgren's Syndrome
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT03627065
- Locations
- ๐บ๐ธ
The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States
๐บ๐ธNorth Georgia Rheumatology Group, Lawrenceville, Georgia, United States
๐บ๐ธAdvanced Pharma CR, Miami, Florida, United States
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT03589651
- Locations
- ๐บ๐ธ
Rutgers Cancer Institute of Nj, New Brunswick, New Jersey, United States
๐บ๐ธUpmc Cancercenter, Pittsburgh, Pennsylvania, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.